Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

Mild Autonomous Cortisol Secretion (MACS) is a condition in which an adrenal gland produces excess cortisol and is associated with high blood pressure, diabetes, and weight gain. Surgical removal of the adrenal gland (adrenalectomy) is standard treatment, but some patients continue to have metabolic health problems after surgery. This randomized study will evaluate whether treatment with tirzepatide after adrenalectomy improves metabolic outcomes in patients with MACS compared with adrenalectomy alone.

NCT Number	NCT07573163
Lead Sponsor	Alaa Sada
Conditions	Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
Enrollment	34 participants
Start Date	2026-07-27
Primary Completion	2028-07-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-30